Summit Therapeutics
SMMT
11 hedge funds and large institutions have $23.1M invested in Summit Therapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
4.36% more ownership
Funds ownership: 0% → 4.36% (+4.4%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
7% less capital invested
Capital invested by funds: $24.8M → $23.1M (-$1.7M)
15% less funds holding
Funds holding: 13 → 11 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.02M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$126K |
| 3 |
Morgan Stanley
New York
|
+$40K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$949K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$534K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$26K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11K |
| 5 |
JCM
Jacobi Capital Management
Pittston,
Pennsylvania
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $7.96M | – | – | – |
|
2
Point72 Asset Management
Stamford,
Connecticut
| $7.93M | – | – | – |
|
|
3
Axa
Paris,
France
| $2.52M | -$949K | -88,954 | -23% |
|
4
First Eagle Investment Management
New York
| $1.5M | – | – | – |
|
|
SFM
5
Sphera Funds Management
Tel Aviv,
Israel
| $1.26M | -$534K | -50,000 | -25% |
|
|
GPCM
6
Granite Point Capital Management
Boston,
Massachusetts
| $1M | +$126K | +11,852 | +11% |
|
|
7
Millennium Management
New York
| $815K | +$1.02M | +95,172 | New |
|
|
8
Morgan Stanley
New York
| $34K | +$40K | +3,750 | +1,500% |
|
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $30K | -$26K | -2,439 | -40% |
|
|
10
UBS Group
Zurich,
Switzerland
| $15K | +$4.93K | +462 | +34% |
|
11
Wells Fargo
San Francisco,
California
| $10K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$11K | -1,213 | Closed |
|
|
JCM
13
Jacobi Capital Management
Pittston,
Pennsylvania
| – | -$7K | -500 | Closed |
|
|
LTFS
14
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -100 | Closed |
|
SMMT Hedge Fund Activity: Q4 2016 in Review
11 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2016, worth a combined $23.1M — down 6.9% from $24.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SMMT and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.02M. The largest seller was Axa, cutting an estimated $949K.
- 11 institutional investors held Summit Therapeutics (SMMT) as of Q4 2016, down from 13 in Q3 2016.
- Funds reported $23.1M of Summit Therapeutics stock for Q4 2016, down 6.9% quarter-over-quarter.
- 1 fund opened new Summit Therapeutics positions in Q4 2016 and 3 closed out, a net change of -2 holders.
- The largest Summit Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $1.02M added.
- The largest Summit Therapeutics seller in Q4 2016 was Axa, an estimated $949K sold.
Based on aggregated 13F filings for Q4 2016.